Rigel Pharmaceuticals, Inc.

Investors News & Events Contact Us
  • Home
  • Who We Are
    • Company Overview
    • Management Team
    • Board of Directors
    • Partners
  • Pipeline
    • Pipeline
      • Clinical Trials
      • Investigator Sponsored Research
      • Expanded Access Policy
    • Proprietary Programs
      • Warm AIHA
      • COVID-19
      • IRAK1/4
      • RIPK1
    • Partnered Programs
      • BerGenBio
      • Daiichi-Sankyo
      • Forma
      • Grifols
      • Kissei
      • Lilly
      • Medison
      • Knight
  • Products
  • Join Our Team
    • Life at Rigel
    • Our Values
    • Benefits
    • Current Openings
  • Investors
  • News & Events
  • Contact Us

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
    • Email Alerts
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • FAQ
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Analyst Coverage
  • Governance
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Press Releases
  • Events & Presentations
  • Email Alerts
Apr 26, 2016 7:30am EDT

Rigel Announces Conference Call and Webcast to Report First Quarter 2016 Financial Results

Apr 12, 2016 7:30am EDT

Rigel Announces Presentations at Upcoming American Association of Cancer Research (AACR) Conference

Apr 01, 2016 7:30am EDT

Rigel Completes Enrollment of FIT Phase 3 Program for Fostamatinib in ITP

Mar 08, 2016 4:05pm EST

Rigel Announces Fourth Quarter and Year End 2015 Financial Results

Mar 08, 2016 4:03pm EST

Rigel Names Anne-Marie Duliege, M.D., M.S. As Chief Medical Officer

Mar 01, 2016 7:30am EST

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2015 Financial Results

Feb 29, 2016 7:30am EST

Rigel to Present at Cowen and Company 36th Annual Health Care Conference

Feb 25, 2016 7:30am EST

Rigel Initiates Phase 2 Clinical Trial Of Fostamatinib In Autoimmune Hemolytic Anemia

Jan 28, 2016 7:30am EST

Rigel Completes Enrollment of First Phase 3 Study of Fostamatinib in ITP (FIT)

Jan 07, 2016 7:30am EST

Rigel Reviews Recent Progress and Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco

  • Previous
  • 1…
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • …36
  • Next
RSS
  • Email Alerts
  • RSS News Feed
Terms of Use Privacy Policy

© 2023 Rigel Pharmaceuticals, Inc. All Rights Reserved.

TAVALISSE, TAVLESSE, RIGEL and the Rigel arc logo are registered trademarks of Rigel Pharmaceuticals, Inc.

REZLIDHIA is a trademark of Rigel Pharmaceuticals, Inc.

Facebook Twitter Linkedin